Management of pregnancy in hereditary angioedema in a resource constrained setting: Our experience at Chandigarh, North India

Immunobiology. 2022 Jan 5;227(2):152175. doi: 10.1016/j.imbio.2022.152175. Online ahead of print.


Hereditary angioedema (HAE) is a rare genetic disorder distinguished clinically by recurrent episodes of non-pruritic swelling. Although pregnancy has been considered a trigger, it may have variable effect on frequency of attacks of HAE. C1-inhibitor (C1-INH) is the treatment of choice for management of HAE during pregnancy. However, because of non-availability of C1-INH therapy in developing countries, fresh-frozen plasma (FFP) and tranexamic acid remain the drugs of choice in pregnancy for treatment of acute attacks and for prophylaxis respectively. There is paucity of data on outcome of pregnancy with patients with HAE from developing countries such as India where all the first line medications are not available. A retrospective review was done including four HAE patients who conceived (with a total of 9 pregnancies). Our results suggest that frequency of attacks may increase during pregnancy especially during second trimester and post-delivery (during breastfeeding). However, HAE attacks are rare at the time of delivery. In resource limited settings, treatment with FFP/tranexamic acid needs to be individualised.

Keywords: C1-inhibitor; Hereditary angioedema; Pregnancy; Tranexamic acid.